An effective means to eradicate latent reservoirs in HIV-1-infected individuals remains elusive. Attempts to purge these reservoirs were undertaken over a decade ago without success. The subsequent lapse in further clinical attempts since may have been justified as our knowledge of the mechanisms which underpin the latent state still evolves. Although additional novel molecular antagonists of HIV-1 latency have subsequently been reported, these candidate agents have not been tested in human trials for reservoir ablation. This review provides an overview of the protein kinase C (PKC) pathway which can be modulated by small molecular agents to induce the expression of latent HIV-1 from within infected reservoir cells. Some of these agents have been tested against select cancers with seemingly tolerable side effects. As such, modulation of the PKC pathway may yet be a viable mechanism toward HIV-1 reservoir eradication. 1. Introduction Administration of highly active anti-retroviral therapy (HAART) to HIV-1-infected individuals results in effective suppression of viral replication in metabolically active cells bearing integrated viral DNA. However, a small population of infected cells is refractive to HAART treatment as a consequence of being quiescent and/or not actively expressing virus products [1–5]. This small population of cells, comprised largely of infected CD4+ resting T cells, constitutes the HAART-persistent latent reservoir. Most cells in this silent reservoir have long half lives [6, 7] and are hidden from immune surveillance which permits them to remain as a stable source for de novo viral production upon reactivation. One strategy for eradication of this reservoir rests upon the premise that cellular activation with concomitant upregulation of viral expression will hasten its elimination [8–11]. Cellular activation typically shortens the half-life of a cell relative to its quiescent counterpart, and a cell, actively expressing viral antigens, would be a more favorable target for immune clearance [12]. Some time ago, several clinical trials were attempted to eradicate or diminish the presence of latent reservoirs using the cellular activators, OKT3 and IL-2, which primarily target T-cell responses [13–18]. These trials were ineffectual although genotypic alterations of reservoir virus in treated individuals were noted [19]. Nonetheless, these attempts clearly indicated that a broader armamentarium of agents or multiple clinical interventions were required to accomplish the elusive goal of complete reservoir eradication. The list of candidates
References
[1]
T. W. Chun, D. Finzi, J. Margolick, K. Chadwick, D. Schwartz, and R. F. Siliciano, “In vivo fate of HIV-1-infected t cells: quantitative analysis of the transition to stable latency,” Nature Medicine, vol. 1, no. 12, pp. 1284–1290, 1995.
[2]
T. W. Chun, L. Stuyver, S. B. Mizell et al., “Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 24, pp. 13193–13197, 1997.
[3]
D. Finzi, M. Hermankova, T. Pierson et al., “Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy,” Science, vol. 278, no. 5341, pp. 1295–1300, 1997.
[4]
J. K. Craigo, B. K. Patterson, S. Paranjpe et al., “Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy,” AIDS Research and Human Retroviruses, vol. 20, no. 11, pp. 1196–1209, 2004.
[5]
A. Jordan, D. Bisgrove, and E. Verdin, “HIV reproducibly establishes a latent infection after acute infection of T cells in vitro,” European Molecular Biology Organization Journal, vol. 22, no. 8, pp. 1868–1877, 2003.
[6]
D. Finzi, J. Blankson, J. D. Siliciano et al., “Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy,” Nature Medicine, vol. 5, no. 5, pp. 512–517, 1999.
[7]
M. C. Strain, H. F. Günthard, D. V. Havlir et al., “Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4819–4824, 2003.
[8]
C. Fraser, N. M. Ferguson, A. C. Ghani et al., “Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs,” AIDS, vol. 14, no. 6, pp. 659–669, 2000.
[9]
J. Kulkosky and R. J. Pomerantz, “Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy,” Clinical Infectious Diseases, vol. 35, no. 12, pp. 1520–1526, 2002.
[10]
R. J. Pomerantz, “Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication,” Clinical Infectious Diseases, vol. 34, no. 1, pp. 91–97, 2002.
[11]
D. D. Richman, D. M. Margolis, M. Delaney, W. C. Greene, D. Hazuda, and R. J. Pomerantz, “The challenge of finding a cure for HIV infection,” Science, vol. 323, no. 5919, pp. 1304–1307, 2009.
[12]
C. A. Janeway Jr., P. Travers, S. Hunt, M. Walport, and M. J. Shlomchik, Immunobiology: The Immune System in Health and Disease, Garland, New York, NY, USA, 6th edition, 2004.
[13]
T. W. Chun, D. Engel, S. B. Mizell et al., “Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy,” Nature Medicine, vol. 5, no. 6, pp. 651–655, 1999.
[14]
S. Emery, W. B. Capra, D. A. Cooper et al., “Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease,” Journal of Infectious Diseases, vol. 182, no. 2, pp. 428–434, 2000.
[15]
J. Kulkosky, G. Nunnari, M. Otero et al., “Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy,” Journal of Infectious Diseases, vol. 186, no. 10, pp. 1403–1411, 2002.
[16]
J. M. Prins, S. Jurriaans, R. M. E. Van Praag et al., “Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy,” AIDS, vol. 13, no. 17, pp. 2405–2410, 1999.
[17]
R. M. E. Van Praag, J. M. Prins, M. T. L. Roos et al., “OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion,” Journal of Clinical Immunology, vol. 21, no. 3, pp. 218–226, 2001.
[18]
C. Fraser, N. M. Ferguson, A. C. Ghani et al., “Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs,” AIDS, vol. 14, no. 6, pp. 659–669, 2000.
[19]
J. Kulkosky, J. Sullivan, Y. Xu et al., “Genotypic alteration of HAART-persistent HIV-1 reservoirs in vivo,” Virology, vol. 314, no. 2, pp. 617–629, 2003.
[20]
J. Kulkosky, J. Sullivan, Y. Xu, E. Souder, D. H. Hamer, and R. J. Pomerantz, “Expression of latent HAART-persistent HIV type 1 induced by novel cellular activating agents,” AIDS Research and Human Retroviruses, vol. 20, no. 5, pp. 497–505, 2004.
[21]
R. Mehla, S. Bivalkar-Mehla, R. Zhang et al., “Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner,” PLoS ONE, vol. 5, no. 6, Article ID e11160, pp. 1–15, 2010.
[22]
M. Pérez, A. G. de Vinuesa, G. Sanchez-Duffhues et al., “Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency,” Current HIV Research, vol. 8, no. 6, pp. 418–429, 2010.
[23]
W. Y. Chen, E. C. Bailey, S. L. McCune, J. Y. Dong, and T. M. Townes, “Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 11, pp. 5798–5803, 1997.
[24]
G. He, L. Ylisastigui, and D. M. Margolis, “The regulation of HIV-1 gene expression: the emerging role of chromatin,” DNA and Cell Biology, vol. 21, no. 10, pp. 697–705, 2002.
[25]
L. Ylisastigui, N. M. Archin, G. Lehrman, R. J. Bosch, and D. M. Margolis, “Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression,” AIDS, vol. 18, no. 8, pp. 1101–1108, 2004.
[26]
D. Demonté, V. Quivy, Y. Colette, and C. Van Lint, “Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies,” Biochemical Pharmacology, vol. 68, no. 6, pp. 1231–1238, 2004.
[27]
T. M. Folks, K. A. Clouse, J. Justement et al., “Tumor necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 7, pp. 2365–2368, 1989.
[28]
R. Ghose, L. Y. Liou, C. H. Herrmann, and A. P. Rice, “Induction of TAK (cyclin T1/P-TEFβ) in purified resting CD4+ T lymphocytes by combination of cytokines,” Journal of Virology, vol. 75, no. 23, pp. 11336–11343, 2001.
[29]
D. D. Scripture-Adams, D. G. Brooks, Y. D. Korin, and J. A. Zack, “Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype,” Journal of Virology, vol. 76, no. 24, pp. 13077–13082, 2002.
[30]
F. X. Wang, Y. Xu, J. Sullivan et al., “IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART,” Journal of Clinical Investigation, vol. 115, no. 1, pp. 128–137, 2005.
[31]
S. F. Steinberg, “Structural basis of protein kinase C isoform function,” Physiological Reviews, vol. 88, no. 4, pp. 1341–1378, 2008.
[32]
M. Spitaler and D. A. Cantrell, “Protein kinase C and beyond,” Nature Immunology, vol. 5, no. 8, pp. 785–790, 2004.
[33]
G. Jones and G. Carpenter, “Regulation of phospholipase C isozymes,” Cytokine and Growth Factor Reviews, vol. 4, no. 2, pp. 97–106, 1992.
[34]
Y. Nishizuka, “Protein kinase C and lipid signaling for sustained cellular responses,” FASEB Journal, vol. 9, no. 7, pp. 484–496, 1995.
[35]
F. C. Stevens, “Calmodulin: an introduction,” Canadian Journal of Biochemistry and Cell Biology, vol. 61, no. 8, pp. 906–910, 1983.
[36]
D. Chin and A. R. Means, “Calmodulin: a prototypical calcium sensor,” Trends in Cell Biology, vol. 10, no. 8, pp. 322–328, 2000.
[37]
K. Shen, M. N. Teruel, J. H. Connor, S. Shenolikar, and T. Meyer, “Molecular memory by reversible translocation of calcium/calmodulin-dependent protein kinase II,” Nature Neuroscience, vol. 3, no. 9, pp. 881–886, 2000.
[38]
U. Kikkawa, Y. Nishizuka, K. Igarashi et al., “Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 13, pp. 4868–4871, 1989.
[39]
J. H. Hurley, A. C. Newton, P. J. Parker, P. M. Blumberg, and Y. Nishizuka, “Taxonomy and function of C1 protein kinase C homology domains,” Protein Science, vol. 6, no. 2, pp. 477–480, 1997.
[40]
N. Márquez, M. A. Calzado, G. Sánchez-Duffhues et al., “Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation,” Biochemical Pharmacology, vol. 75, no. 6, pp. 1370–1380, 2008.
[41]
V. E. Marquez and P. M. Blumberg, “Synthetic diacylglycerols (DAG) and DAG-lactones as activators of protein kinase C (PK-C),” Accounts of Chemical Research, vol. 36, no. 6, pp. 434–443, 2003.
[42]
S. Zayed, A. Hafez, W. Adolf, and E. Hecker, “New tigliane and daphnane derivatives from Pimelea prostrata and Pimelea simplex,” Experientia, vol. 33, no. 12, pp. 1554–1555, 1977.
[43]
P. A. Cox, “Will tribal knowledge survive the millennium?” Science, vol. 287, no. 5450, pp. 44–45, 2000.
[44]
K. R. Gustafson, J. H. Cardellina, J. B. McMahon et al., “A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1,” Journal of Medicinal Chemistry, vol. 35, no. 11, pp. 1978–1986, 1992.
[45]
R. J. Gulakowski, J. B. McMahon, R. W. Buckheit, K. R. Gustafson, and M. R. Boyd, “Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV),” Antiviral Research, vol. 33, no. 2, pp. 87–97, 1997.
[46]
J. Kulkosky, D. M. Culnan, J. Roman et al., “Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART,” Blood, vol. 98, no. 10, pp. 3006–3015, 2001.
[47]
Y. D. Korin, D. G. Brooks, S. Brown, A. Korotzer, and J. A. Zack, “Effects of prostratin on T-cell activation and human immunodeficiency virus latency,” Journal of Virology, vol. 76, no. 16, pp. 8118–8123, 2002.
[48]
D. G. Brooks, D. H. Hamer, P. A. Arlen et al., “Molecular characterization, reactivation, and depletion of latent HIV,” Immunity, vol. 19, no. 3, pp. 413–423, 2003.
[49]
S. A. Trushin, G. D. Bren, S. Asin, K. N. Pennington, C. V. Paya, and A. D. Badley, “Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCα and PKCθ,” Journal of Virology, vol. 79, no. 15, pp. 9821–9830, 2005.
[50]
X. Yang, Y. Chen, and D. Gabuzda, “ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-κB,” Journal of Biological Chemistry, vol. 274, no. 39, pp. 27981–27988, 1999.
[51]
S. A. Williams, L. F. Chen, H. Kwon et al., “Prostratin antagonizes HIV latency by activating NF-κB,” Journal of Biological Chemistry, vol. 279, no. 40, pp. 42008–42017, 2004.
[52]
A. J. Whitmarsh and R. J. Davis, “Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways,” Journal of Molecular Medicine, vol. 74, no. 10, pp. 589–607, 1996.
[53]
N. D. Perkins, N. L. Edwards, C. S. Duckett, A. B. Agranoff, R. M. Schmid, and G. J. Nabel, “A cooperative interaction between NF-κB and Sp1 is required for HIV-1 enhancer activation,” European Molecular Biology Organization Journal, vol. 12, no. 9, pp. 3551–3558, 1993.
[54]
K. A. Jones and B. M. Peterlin, “Control of RNA initiation and elongation at the HIV-1 promoter,” Annual Review of Biochemistry, vol. 63, pp. 717–743, 1994.
[55]
D. A. Joyce and J. H. Steer, “Differentiation of the U-937 promonocytic cell line induced by phorbol myristate acetate or retinoic acid: effect of aurothiomalate,” Agents and Actions, vol. 37, no. 3-4, pp. 305–310, 1992.
[56]
R.V. Davis, L. McKernan, and J. Kulkosky, “In vivo effects of antiviral protein kinase C modulators on zebrafish development and survival,” ISRN Toxicology, vol. 2011, Article ID 248280, p. 7, 2011.
[57]
G. Furstenberger, D. L. Berry, B. Sorg, and F. Marks, “Skin tumor promotion by phorbol esters is a two-stage process,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 12, pp. 7722–7726, 1981.
[58]
A. M. Michie and R. Nakagawa, “The link between PKCα regulation and cellular transformation,” Immunology Letters, vol. 96, no. 2, pp. 155–162, 2005.
[59]
Z. Szallasi, L. Krsmanovic, and P. M. Blumberg, “Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin,” Cancer Research, vol. 53, no. 11, pp. 2507–2512, 1993.
[60]
D. H. Hamer, S. Bocklandt, L. McHugh et al., “Rational design of drugs that induce human immunodeficiency virus replication,” Journal of Virology, vol. 77, no. 19, pp. 10227–10236, 2003.
[61]
R. K. Strair, D. Schaar, L. Goodell et al., “Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate,” Clinical Cancer Research, vol. 8, no. 8, pp. 2512–2518, 2002.
[62]
H. J. Mackay and C. J. Twelves, “Protein kinase C: a target for anticancer drugs?” Endocrine-Related Cancer, vol. 10, no. 3, pp. 389–396, 2003.
[63]
A. R. Clamp, F. H. Blackball, P. Vasey et al., “A phase II trial of bryostatin-1 administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinoma,” British Journal of Cancer, vol. 89, no. 7, pp. 1152–1154, 2003.
[64]
J. Kulkosky and S. Bray, “HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication,” Current HIV Research, vol. 4, no. 2, pp. 199–208, 2006.
